Sartorius Stedim Biotech (SSB) has announced BioOutsource’s new microsite will detail Sartorius Stedim Cellca’s cell line and upstream process development services.
The new microsite features insights into the technology and development services of Cellca most recently acquired by SSB. The availability of both subsidiaries’ unique range of integrated services will support biopharma companies to rapidly and cost-effectively develop their biologics and biosimilars.
The new microsite divides into four easy-to-navigate sections, which explain Cellca’s unique CHO Expression Platform including Expression Vector, Host Cell Line, CHO Media System and Upstream Process Design. This structure gives a simple overview of the technical details and time-saving benefits of this robust, scalable expression platform for individual applications.
Cellca’s cell line and upstream process development services complement BioOutsource’s broad range of bioanalytical and biosafety testing, as well as pre-qualified biosimilar assays. As a result, scientists and potential customers can source all their needs for developing biologics and biosimilars from one trusted supplier.
In addition, as both Cellca and BioOutsource have been part of Sartorius Stedim Biotech since 2015 biopharma firms with a need to commercialise biologics will not only benefit from this niche expertise but can also access Sartorius Stedim Biotech’s extensive global upstream process development capabilities to accelerate the development timeline of their biologics and biosimilars.
Managing Director of Sartorius Stedim’s BioOutsource Gerry MacKay commented: "We’re pleased to be launching our new microsite because it signals the availability of our unique integrated services.
"Developers of biologics and biosimilars can now go to our site to find out how to access a fully integrated pathway from cell line development and data characterisation through to upstream process development. They can also discover how these services will support them to comply with regulatory standards for timely, cost-effective development of their biosimilars."